PROFESSIONAL EDITION

The largest community of pharma leaders

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for f

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles